Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S.

MUMBAI Fri May 2, 2014 7:26am EDT

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. REUTERS/Ajay Verma

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013.

Credit: Reuters/Ajay Verma

Related Topics

MUMBAI (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.

The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy's Ohm Labs plant in New Jersey, which is the company's only facility making generics for the United States. (r.reuters.com/nuk98v)

All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.

Rival Indian drugmaker Sun Pharmaceutical Industries Ltd agreed to buy Ranbaxy last month in a $3.2 billion deal, betting it can fix Ranbaxy's problems.

The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.

Ranbaxy did not immediately respond to requests for comment.

(Reporting by Zeba Siddiqui in MUMBAI; Editing by Subhranshu Sahu)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
cleverboots21 wrote:
Ranbaxy has a history of poor quality control. I’m betting Sun will not be able to fix the problems attributed to Ranbaxy. Wouldn’t we all be safer if the company were shut down rather than sold AGAIN?

May 02, 2014 2:58pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Pictures